United States Últimas notícias

Motorola Solutions (NYSE:MSI) announced that its board of directors approved a regular quarterly cash dividend of $1.21 per share.

On this episode of Stock Movers: - Shares of Moderna (MRNA) surged by a record 101% - the stock's biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck & Co.'s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday. - Shares of Estee Lauder (EL) rallied after the beauty company's adjusted earnings per share and sales metrics topped consensus expectations for the fourth quarter. The midpoint of fiscal 2027 organic sales and adjusted EPS guidance ranges are above Street views. - Shares of La-Z-Boy (LZB) tumbled at the open after the furniture maker's forecast sales for the second quarter missed the average analyst estimate.

Scott Painter, chief executive officer of TrueCar, says automakers' incentives in "very soft new-car market'' are helping cushion consumers from the blow of tariffs like those being threatened by President Donald Trump against Canada. He speaks with Dani Burger on Bloomberg's "Open Interest.''

Joe Feldman, senior research analyst and assistant director of research at Telsey, says there is a "strong signal that the turnaround is working" at Target. The retailer lifted its full-year guidance after results outpaced estimates in the second-quarter.

Betterment CEO Sarah Levy sounds the alarm on Gen Z treating sports betting like investing. She joins Open Interest to explain why gambling apps, social-media financial advice and speculative trading are blurring the line between entertainment and long-term wealth building and why investors need stronger guardrails.

Target's turnaround may finally be working. Telsey Advisory Group Senior Managing Director and Assistant Director of Research Joseph Feldman joined Bloomberg Open Interest to break down why stronger traffic, sharper merchandising and a revamped food strategy are bringing shoppers back, even without tariff refunds. He also explains why Target shouldn't copy Walmart and which struggling retailers could lose the most market share.

Shares of Moderna and Merck soared on Wednesday morning after a study showed that a vaccine they produced had promising results when it comes to fighting skin cancer. A late-stage trial showed that the mRNA vaccine helped reduce the recurrence of melanoma. Sam Fazeli of Bloomberg Intelligence has more.

Keith Lerner, CIO & Chief Market Strategist at Truist, joins Bloomberg's Vonnie Quinn on "Bloomberg Brief" to discuss market expectations beyond the recent jitters amid a historic earnings season.

SK Hynix shares surged following the announcement of a nearly $30 billion share buyback program. Bloomberg's Ed Ludlow explains that the buyback aims to stabilize the stock after significant volatility, with shares having risen sharply in previous years but declining since June.

Femasys (NASDAQ:FEMY) announced that the U.S. FDA approved its modular premarket approval submission approach for FemBloc, the company’s investigational non-surgical permanent birth control technology.

Gennadiy Goldberg, TD Securities head of US rates strategy, says interest rate hikes by the Federal Reserve could help flatten the yield curve. But he believes the Fed is going to try and hold rates steady. He speaks on "Bloomberg Surveillance."

Merck and Moderna announced positive results from a large late-stage trial of their personalized mRNA cancer vaccine, which significantly reduced the recurrence of melanoma, the deadliest form of skin cancer. Madison Muller reports on "Bloomberg Open Interest."